<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04965636</url>
  </required_header>
  <id_info>
    <org_study_id>215360</org_study_id>
    <nct_id>NCT04965636</nct_id>
  </id_info>
  <brief_title>Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE)</brief_title>
  <acronym>SPHERE</acronym>
  <official_title>A 52-week, Open-label, Single Arm Study to Investigate the Efficacy and Safety of Mepolizumab SC in Participants Aged 6 to 17 Years With Hypereosinophilic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy and safety of mepolizumab in&#xD;
      children and adolescents with hypereosinophilic syndrome (HES) who are receiving standard of&#xD;
      care (SoC) therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 14, 2022</start_date>
  <completion_date type="Anticipated">September 23, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 23, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a single arm study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This is an open-label study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of HES flares experienced by participants per year</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>The annualized rate of HES flares will be measured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mean daily oral corticosteroids (OCS) dose (prednisone/prednisolone or equivalent) from Weeks 0 to 4 to Weeks 48 to 52</measure>
    <time_frame>Weeks 0 to 4 and Weeks 48 to 52</time_frame>
    <description>Change in mean daily OCS dose (prednisone/prednisolone or equivalent) will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with &gt;=50 percent (%) reduction in mean daily OCS dose (prednisone/prednisolone or equivalent) from Weeks 0 to 4 compared with Weeks 48 to 52</measure>
    <time_frame>Weeks 0 to 4 and Weeks 48 to 52</time_frame>
    <description>Number of participants with &gt;=50% reduction in mean daily OCS dose (prednisone/prednisolone or equivalent) will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants achieving a mean daily OCS dose (prednisone/prednisolone or equivalent) of &lt;=7.5 milligrams (mg) during Weeks 48 to 52 in participants that are taking OCS at Baseline</measure>
    <time_frame>Weeks 48 to 52</time_frame>
    <description>Number of participants achieving a mean daily OCS dose (prednisone/prednisolone or equivalent) of &lt;=7.5 mg will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants achieving a mean daily OCS dose (prednisone/prednisolone or equivalent) of &lt;=7.5 mg during Weeks 48 to 52</measure>
    <time_frame>Weeks 48 to 52</time_frame>
    <description>Participants achieving mean daily OCS dose (prednisone/prednisolone or equivalent) of &lt;=7.5 mg will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in fatigue severity based on Brief Fatigue Inventory (BFI) Item 3 (worst level of fatigue during past 24 hours) for Week 52</measure>
    <time_frame>Baseline and up to Week 52</time_frame>
    <description>Item 3 of the BFI is a 11-point scale that measures fatigue (weariness, tiredness) ranging from 0 &quot;no fatigue&quot; to 10 &quot;as bad as you can imagine&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Anti-drug antibodies (ADA) and neutralizing antibodies (NAb)</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Participants with ADA and NAb will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio to Baseline in absolute blood eosinophil count</measure>
    <time_frame>Baseline and up to Week 52</time_frame>
    <description>Blood samples will be collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mepolizumab plasma concentrations</measure>
    <time_frame>Week 4 and up to Week 52</time_frame>
    <description>Blood samples will be collected for determination of mepolizumab plasma concentration.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Hypereosinophilic Syndrome</condition>
  <arm_group>
    <arm_group_label>Participants receiving mepolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mepolizumab</intervention_name>
    <description>Mepolizumab will be provided in pre-filled safety syringe</description>
    <arm_group_label>Participants receiving mepolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must be aged 6 to 17 years inclusive, at Screening (Visit 1).&#xD;
&#xD;
          -  Participants who have been diagnosed with HES for at least 6 months prior to enrolment&#xD;
             (Visit 2).&#xD;
&#xD;
          -  A history of 2 or more HES flares within the past 12 months prior to Screening (Visit&#xD;
             1).&#xD;
&#xD;
          -  Participants must have blood eosinophil count &gt;=1000 cells per microliter (/mcL)&#xD;
             present at Screening.&#xD;
&#xD;
          -  Participants must be on a stable dose of HES therapy for the 4 weeks prior to the&#xD;
             first dose of mepolizumab (Visit 2)&#xD;
&#xD;
          -  Male and/or female&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Life-threatening HES or life-threatening HES co-morbidities&#xD;
&#xD;
          -  Other concurrent medical conditions that may affect the participant's safety&#xD;
&#xD;
          -  Eosinophilia of unknown significance&#xD;
&#xD;
          -  Fusion tyrosine kinase gene translocation [FIP1L1- Platelet-derived Growth Factor&#xD;
             Receptor (PDGFRÎ±) (F/P)] positivity&#xD;
&#xD;
          -  Clinical diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA)&#xD;
&#xD;
          -  Participants with chronic or ongoing active infections requiring systemic treatment,&#xD;
             as well as participants who have experienced clinically significant infections due to&#xD;
             viruses, bacteria, and fungi within 4 weeks prior to enrolment (Visit 2)&#xD;
&#xD;
          -  Participants with a pre-existing parasitic infestation within 6 months prior to&#xD;
             enrolment (Visit 2)&#xD;
&#xD;
          -  Participants with a known immunodeficiency (e.g. Human immunodeficiency virus [HIV]),&#xD;
             other than that explained by the use of OCS or other therapy taken for HES&#xD;
&#xD;
          -  Participants with documented history of any clinically significant cardiac damage&#xD;
             prior to Screening (Visit 1) that, in the opinion of the investigator, would impact&#xD;
             the participant's participation during the study&#xD;
&#xD;
          -  Participants with a history of or current lymphoma, Participants with current&#xD;
             malignancy or previous history of cancer in remission for less than 12 months prior to&#xD;
             Screening (Visit 1)&#xD;
&#xD;
          -  Participants who are not responsive to OCS based on clinical response or blood&#xD;
             eosinophil counts.&#xD;
&#xD;
          -  Participants who have previously received mepolizumab in the 4 months prior to&#xD;
             enrolment (Visit 2)&#xD;
&#xD;
          -  Participants receiving non-oral systemic corticosteroids in the 4-week period prior to&#xD;
             enrolment (Visit 2).&#xD;
&#xD;
          -  Participants who have received any other monoclonal antibodies within 30 days or 5&#xD;
             half-lives, whichever is longer, of enrolment (Visit 2).&#xD;
&#xD;
          -  Participants who have received treatment with an investigational agent (biologic or&#xD;
             non-biologic) within the past 30 days or 5 drug half-lives, whichever is longer, prior&#xD;
             to enrolment (Visit 2).&#xD;
&#xD;
          -  Use of candidate Coronavirus disease 2019 (COVID-19) vaccines that have not received&#xD;
             limited, accelerated, or full authorization/approval, and are only in use as part of a&#xD;
             clinical trial.&#xD;
&#xD;
          -  Participants who are currently participating in any other interventional clinical&#xD;
             study&#xD;
&#xD;
          -  Participants with any history of hypersensitivity to any monoclonal antibody&#xD;
             (including mepolizumab).&#xD;
&#xD;
          -  Evidence of clinically significant abnormality in the hematological, biochemical, or&#xD;
             urinalysis screen from the sample collected at Screening (Visit 1), that could put the&#xD;
             participant's safety at risk by participating in the study, as judged by the&#xD;
             investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EU GSK Clinical Trials Call Center</last_name>
    <phone>+44 (0) 20 89904466</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 7, 2021</study_first_submitted>
  <study_first_submitted_qc>July 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypereosinophilic Syndrome</keyword>
  <keyword>Mepolizumab</keyword>
  <keyword>Safety</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Adolescent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypereosinophilic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

